Bristol-Myers Squibb Company (BMY)vsQMMM Holdings Limited Ordinary Shares (QMMM)
BMY
Bristol-Myers Squibb Company
$58.94
+2.70%
HEALTHCARE · Cap: $120.03B
QMMM
QMMM Holdings Limited Ordinary Shares
$119.40
0.00%
COMMUNICATION SERVICES · Cap: $6.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 2568466% more annual revenue ($48.19B vs $1.88M). BMY leads profitability with a 14.6% profit margin vs -1.5%. BMY earns a higher WallStSmart Score of 64/100 (C+).
BMY
Buy64
out of 100
Grade: C+
QMMM
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.0%
Fair Value
$161.93
Current Price
$58.94
$102.99 discount
Intrinsic value data unavailable for QMMM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
1.3% revenue growth
Distress zone — elevated risk
Elevated debt levels
0.0% earnings growth
Weak financial health signals
Trading at 519.1x book value
ROE of -2.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.
Bull Case : QMMM
The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.
Bear Case : BMY
The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : QMMM
The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
BMY profiles as a value stock while QMMM is a turnaround play — different risk/reward profiles.
BMY is growing revenue faster at 1.3% — sustainability is the question.
BMY generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BMY scores higher overall (64/100 vs 14/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →QMMM Holdings Limited Ordinary Shares
COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA
QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?